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Pancreatic cancer is the fourth leading cause of cancer death with a median survival of
6months and a dismal 5-year survival rate of 3–5%. The development and progression of
pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor sup-
pressor genes, and the deregulation of many signaling pathways.Therefore, the strategies
targeting these molecules as well as their downstream signaling could be promising for
the prevention and treatment of pancreatic cancer. However, although targeted therapies
for pancreatic cancer have yielded encouraging results in vitro and in animal models, these
ﬁndings have not been translated into improved outcomes in clinical trials.This failure is due
to an incomplete understanding of the biology of pancreatic cancer and to the selection of
poorly efﬁcient or imperfectly targeted agents. In this review, we will critically present the
current knowledge regarding the molecular, biochemical, clinical, and therapeutic aspects
of pancreatic cancer.
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INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer death with
a median survival of 6months and a dismal 5-year survival rate
of 3–5% and this ﬁgure has remained relatively unchanged over
the past 25 years (Jemal et al., 2006). Even for patients diagnosed
with local disease, the 5-year survival rate is only 15%. Known
risk factors for the disease include cigaret smoking, chronic and
hereditary pancreatitis, late-onset diabetes mellitus, and familial
cancer syndromes. The lethal nature of pancreatic cancer stems
from its propensity to rapidly disseminate to the lymphatic system
and distant organs. The presence of occult or clinical metastases at
the time of diagnosis together with the lack of effective chemother-
apies contributes to the high mortality in patients with pancreatic
cancer. Pancreatic cancer is one of the most intrinsically drug-
resistant tumors and resistance to chemotherapeutic agents is a
major cause of treatment failure in pancreatic cancer. Gemcitabine
is the standard chemotherapeutic drug for patients with advanced
pancreatic cancer after a phase III trial in 1997 that demonstrated
a modest survival advantage of this agent over 5-FU (median
survival 5.65 versus 4.41months, respectively), but surprisingly
this treatment improved alleviation of disease-related symptoms
(Burris et al., 1997). Very recently, a polychemotherapy regimen
combining 5-FU, irinotecan, and oxaliplatin (FOLFIRINOX) was
shown to nearly double overall survival compared to gemcitabine,
at the expense of a manageable but increased toxicity, limiting
its use to good performance status patients. In addition, overall
survival was less than 12months (Conroy et al., 2011). Therefore,
there is a dire need for designing new and targeted therapeutic
strategies that can overcome the drug-resistance and improve the
clinical outcome for patients diagnosed with pancreatic cancer.
For this purpose, the knowledge on the molecular aspects of pan-
creatic cancer is very important and is likely to be helpful in the
design of new drugs and the molecular selection of existing drugs
for targeted therapy. In the following sections we will summarize
what is known regarding the precursor lesions of pancreatic can-
cer, the molecular aspects of pancreatic cancer, and how some of
these molecular pathways could be exploited for the prevention
or treatment of pancreatic cancer. In addition, we will describe
the current knowledge on other major factors of pancreatic can-
cer development such as inﬂammation, telomerases, angiogenesis,
miRNA, epigenetics and genetics factors, and pancreatic cancer
stem cells, presently under study as possible therapeutic targets.
We will also present the therapeutic strategies currently available.
Finally, we will describe some promising chemopreventive agents
and some new anticancer drugs which are in development.
PANCREATIC CANCER PRECURSOR LESIONS
It is supposed, although not formally established, that like
other epithelial cancers pancreatic cancers do not arise de novo
but undergo a stepwise progression through histologically well-
deﬁned non-invasive precursor lesions, culminating in frank,
invasive neoplasia. Although putative precursor lesions of pan-
creatic cancer were ﬁrst documented over a century ago, it was
only at the end of the last century that several lines of evidence
began to associate invasive pancreatic cancer with these lesions.
For example, autopsy studies conﬁrmed that the prevalence of
what is now recognized as precursor lesions increased with age,
thus paralleling the frequency of invasive pancreatic cancer. Sim-
ilarly, most surgically resected pancreas harboring invasive cancer
also showed the presence of non-invasive intra-ductular lesions
in the surrounding parenchyma, suggesting an etiologic associa-
tion (Cubilla and Fitzgerald, 1976; Andea et al., 2003; Schwartz
and Henson, 2007). Most importantly, careful molecular analyses
over the last 10 years have unequivocally demonstrated that these
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precursor lesions share many of the underlying genetic alterations
observed in the inﬁltrating cancer, underscoring their precursor
status (Brat et al., 1998; Brockie et al., 1998). By the late 1990s,
several terminologies were in use to describe these non-invasive
ductal lesions, leading to considerable difﬁculties in comparing
inter-institutional studies. Fortunately, in 1999 emerged a consen-
sus nomenclature for precursor lesions of pancreatic cancer. The
“pancreatic intraepithelial neoplasia” (PanIN) scheme for classi-
fying these lesions, ﬁrst proposed by Klimstra and Longnecker,
has since become a gold standard at academic centers worldwide
(Hruban et al., 2001, 2004). Brieﬂy,PanINs aremicroscopic lesions
in the smaller (less than 5mm) pancreatic ducts. PanINs can
be papillary or ﬂat, and are composed of columnar to cuboidal
cells with varying amounts of mucin. PanINs are classiﬁed into
four groups, PanIN-1A, PanIN-1B (low-grade PanINs), PanIN-2
(intermediate grade PanINs), and PanIN-3 (high-grade PanINs),
reﬂecting a progressive increase in histologic grade culminating
in invasive neoplasia. PanIN lesions of the lowest grade can be
ﬂat (1A) or papillary (1B) but are characterized by absence of
nuclear abnormalities and conserved nuclear polarity. PanIN-2
lesions are architecturally slightly more complex than PanIN-1
lesions and show more nuclear changes including loss of nuclear
polarity, nuclear crowding, variation in nuclear size (pleomor-
phism), nuclear hyperchromasia, and nuclear pseudostratiﬁca-
tion. Mitoses are rarely seen. In contrast, PanIN-3 lesions, also
referred to as “carcinoma-in situ,” demonstrate widespread loss
of polarity, nuclear abnormalities, and frequent mitoses. How-
ever, as a pre-invasive lesion, PanIN-3 is still contained within the
basement membrane.
If PanINs are the most common proposed precursor lesions for
pancreatic cancer, they are not the only ones. Intraductal papil-
lary mucinous neoplasms (IPMNs) are other precursor lesions, so
called because they typically present as radiologically detectable
cysts in the pancreas (Winter et al., 2006). IPMNs are mucin-
producing epithelial neoplasms, which arise within the main pan-
creatic duct or one of its branches, and have often, although not
always, a papillary architecture (Schmitz-Winnenthal et al., 2003;
Hruban et al., 2004). By deﬁnition, IPMNs are found in the larger
pancreatic ducts. Those that involve the main pancreatic ducts are
designated“mainduct type,”while those that involve the secondary
branches of the main pancreatic duct are designated “branch duct
type” (Hruban et al., 2004; Longnecker et al., 2005). Similar to
PanINs, the cystic precursor lesions also demonstrate a multistep
histological and genetic progression to invasive neoplasia.
MOLECULAR MECHANISMS INVOLVED IN THE
PATHOGENESIS OF PANCREATIC CANCER
Intensive investigation of molecular pathogenesis will help iden-
tifying useful molecules for diagnosis, treatment, and prognosis
of pancreatic cancer. In the last years, considerable research has
focused on identifyingmolecular events associatedwith pancreatic
carcinogenesis and their correlation with the pathological status.
Multiple subsets of genes were found to be activated or inactivated
during the development and progression of pancreatic cancer. The
activation of oncogenes and the inactivation of tumor suppressor
genes are in part responsible for the initiation and progression
of pancreatic cancers. Moreover, the deregulation of molecules
FIGURE 1 | Altered genes in pancreatic cancer. At the upper part, in red,
are shown the gene alterations with gain-of-function, and at the lower part,
in green, are showed the genes with lost-of-function, that promote
pre-cancerous lesions PanIN and IPMN, PDAC, and metastasis.
in several signaling pathways, such as EGFR, Akt, NFκB, CCKR,
Hedgehog, etc., and their molecular crosstalk also play impor-
tant roles in the molecular pathogenesis of pancreatic cancer (see
Figure 1).
ACTIVATION OF ONCOGENES
THE Ras ACTIVATED PATHWAY
Oncogenes can be activated through differentmechanisms includ-
ing point mutation and ampliﬁcation. The activation of the ras
oncogene has been observed in more than 90% of pancreatic can-
cers (Almoguera et al., 1988). The ras gene family encodes three
21-kDa membrane-bound proteins involved in signal transduc-
tion and mediating pleiotropic effects including cell proliferation
andmigration.Activated ras is involved in growth factor-mediated
signal transduction pathways. About 80–90% of pancreatic can-
cers harbor point mutations at codons 12, 13, and 61 in K-ras
(Almoguera et al., 1988). This is the highest level of K-ras alter-
ation found in any human tumor type. The point mutation leads
to the generation of a constitutively active form of ras. The con-
stitutively activated ras binds to GTP and gives uncontrolled
stimulation signals to downstream signaling cascades, promoting
uncontrolled cell growth. K-ras mutations in pancreatic cancer
typically develop during the early phase of carcinogenesis and
patients with mutated K-ras have a shorter survival than patients
with wild-type K-ras, suggesting that the mutation of K-ras par-
ticipates in the initiation and progression of pancreatic cancer.
In addition to point mutations, ampliﬁcation of ras is also fre-
quently observed in pancreatic cancers, suggesting that activation
of the ras oncogene is an important molecular event in pancreatic
cancers.
A peptide vaccine that aims to stimulate immunity against
cancer cells with mutant Ras proteins has been tested as an adju-
vant treatment in patients with pancreatic cancer (Toubaji et al.,
2008). An extension to this research investigated the effects of
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combination therapy with mutant Ras peptide plus granulocyte–
macrophage colony-stimulating factor (Gjertsen et al., 2001). For
Ras to function, it must undergo post-translational modiﬁcation
so that it can attach to the cell membrane. One essential step
involves the addition of a 15-carbon isoprenoid chain, mediated
by farnesyltransferase. The therapeutic use of tipifarnib, a farne-
syltransferase inhibitor (FTI), in combination with gemcitabine
was disappointing in a phase III trial (Van Cutsem et al., 2004).
This ﬁnding could be partly explained by the fact that K-ras can be
alternatively prenylated by the addition of a 20-carbon isoprenoid
moiety mediated by the enzyme geranylgeranyltransferase. More-
over, FTIs work largely by inhibition of the cell cycle, but gem-
citabine needs cell cycle progression to be effective. To this end,
a dual inhibitor of farnesyltransferase and geranylgeranyltrans-
ferase (L-778,123) was tested in a phase I trial in combination with
radiotherapy for locally advanced pancreatic cancer (Martin et al.,
2004). Inhibition of farnesylation and sensitivity to radiotherapy
was demonstrated in a patient-derived cell line. Further develop-
ment of this drugwas,nevertheless,haltedowing to adverse cardiac
effects. Other compounds that are in early phases of clinical test-
ing after yielding promising laboratory results include romidepsin,
a histone deacetylase inhibitor that inhibits Ras-mediated signal
transduction and thus causes cell cycle arrest, and farnesylthios-
alicylic acid (salirasib), which disrupts Ras from its membrane-
binding site. These compounds seem to have clinical activity in
combination with gemcitabine and further studies are necessary.
MAP2K, the principal downstream component of Ras signaling,
has also been the subject of targeted inhibition. In a phase II trial,
the inhibitor CI-1040 (PD184532) did not demonstrate enough
anti-tumor activity to justify further development (Rinehart et al.,
2004). Nevertheless, combined inhibition of MAP2K and other
kinases (such as EGFR) has been effective in preclinical studies,
which suggests that this approach might still have a role in ther-
apy for pancreatic cancer (Jimeno et al., 2007; Takayama et al.,
2008).
THE NOTCH PATHWAY
Notch has also been considered as an oncogene involved in the
pathogenesis of pancreatic cancer (Miyamoto et al., 2003). So
far, four Notch genes have been identiﬁed (Notch-1, Notch-
2, Notch-3, and Notch-4) and ﬁve Notch ligands (Dll-1, Dll-
3, Dll-4, Jagged-1, and Jagged-2) have been found in mam-
mals. Notch protein can be activated by interacting with its
ligands. Upon activation, Notch protein is cleaved by the γ-
secretase, releasing intracellular Notch which translocates into
the nucleus. The intracellular Notch associates with transcrip-
tional factors which regulate the expression of target genes and
thus play an important role in both organ development and
pancreatic carcinogenesis. In fact, Notch signaling is frequently
deregulated in human pancreatic cancers (Buchler et al., 2005;
Wang et al., 2006c,e). Notch signaling occurs downstream of Ras,
EGFR, and TGF-α signaling in pancreatic tumorigenesis and pro-
motes tumor vascularization. Down-regulation of Notch-1 with
siRNA or curcumin (owing to the crosstalk between Notch and
NFκB signaling pathways) can inhibit cell growth and induce
apoptosis in pancreatic cancer cell lines in vitro (Wang et al.,
2006a,d).
THE CYCLOOXYGENASE PATHWAY
The cyclooxygenase (COX) enzymes promote the formation of
prostaglandins, leading to the induction of cell growth. There
are two isoforms of the COX enzyme. COX-1 is produced at
a constant rate and the prostaglandins formed are involved in
several normal physiologic events. COX-2, in contrast, is an
inducible enzyme, absent from most normal tissues. However,
its synthesis is stimulated in inﬂammatory and carcinogenic
processes by cytokines, growth factors, and other cancer pro-
moters. COX-2 has been shown to be increased in a variety of
cancers including pancreatic cancers. Several pancreatic cancer
cell lines strongly express COX-2. Immunohistochemical stud-
ies have shown that about 50% of human pancreatic cancers
over-express COX-2 and that COX-2 mRNA expression is much
higher in tumors than in normal surrounding tissue (Okami
et al., 1999). Moreover, there is a positive association between
ras mutation and COX-2 level because activated ras increases
the stability of COX-2 mRNA. Therefore, COX-2 appears to
be of signiﬁcance in pancreatic carcinogenesis and a crosstalk
between ras, NFκB, Notch, and COX-2 in cellular signaling
might contribute to the molecular pathogenesis of pancreatic
cancer.
As indicated above, COX-2 and its metabolic product (PGE2)
play important roles in pancreatic cancer, suggesting that target-
ing COX-2 could provide a therapeutic beneﬁt. Several COX-2
inhibitors have shown activity in reducing tumor growth with dif-
ferent mechanisms. Indomethacin, one of the COX-2 inhibitors,
inhibits both isoforms of the COX enzyme while newer agents,
such as celecoxib, inhibit only COX-2 and are more desirable for
clinical use. In an orthotopic pancreatic cancer animalmodel, cele-
coxib treatment showed inhibition of tumor growth, angiogenesis,
andmetastasis (Wei et al., 2004). Non-steroidal anti-inﬂammatory
drugs (NSAIDs) also show their inhibitory effect on COX-2 and
PGE2, leading to a reduced incidence of tumor formation and a
reduced number of tumors per animal. Experiments using two
NSAIDs, sulindac and NS398, in pancreatic cancer cell lines, have
shown that both agents cause a dose-dependent inhibition of can-
cer cell growth.A combination of the agents, celecoxib andZyﬂo (a
5-lipoxygenase inhibitor), has shown a reduction in the incidence
and size of pancreatic tumors, and a reduced number of liver
metastases in animal model. It has been reported that celecoxib
potentiates gemcitabine-induced growth inhibition through the
down-regulation of NFκB activation and induction of apoptosis
in pancreatic cancer cells (El-Rayes et al., 2004). In a clinical trial,
patients with advanced pancreatic adenocarcinoma were given
celecoxib in combination with 5-ﬂuorouracil. Such association
was capable of inducing durable and objective responses, even
in gemcitabine-resistant pancreatic cancer (Milella et al., 2004).
These results collectively suggest that COX-2 inhibition with other
novel agents could be useful in future clinical trials for pancreatic
cancer.
THE HEPATOCYTE GROWTH FACTOR RECEPTOR PATHWAY
The MET oncogene, which encodes the receptor for hepato-
cyte growth factor (HGF), is overexpressed in 78% of pancreatic
cancers (Furukawa et al., 1995). HGF is normally produced by
mesenchymal cells and acts on epithelial cells to promote tissue
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regeneration. In hypoxic conditions, however, tumor-associated
ﬁbroblasts produce HGF, which stimulates angiogenesis and
tumor growth, enhances cell motility and extracellular matrix
breakdown and leads to invasion and metastasis. Targeting the
HGF pathway with use of a synthetic competitive antagonist of
HGF (Tomioka et al., 2001) and an antibody against the MET
receptor (Jin et al., 2008) has yielded encouraging results in the
laboratory setting. ARQ 197 is a MET receptor tyrosine kinase
inhibitor that is currently being tested in a phase II trial. A phase I
study showed that it was well-tolerated by patients (Munshi et al.,
2010).
THE INSULIN-LIKE GROWTH FACTOR PATHWAY
The insulin-like growth factor I (IGF-I) receptor,a transmembrane
tyrosine kinase receptor, is overexpressed in 64% of pancreatic
cancers (Hakam et al., 2003). The IGF-I receptor has antiapop-
totic and growth-promoting effects and acts via multiple signal-
ing cascades, including the PI3-Akt, MAPK, and STAT pathways.
Inhibition of the IGF-I receptor by the tyrosine kinase inhibitor
NVP-AEW541, a dominant-negative mutant, and RNA interfer-
ence have all been shown to reduce the growth of pancreatic cancer
cells in vitro and in vivo, and increase chemotherapy-induced or
radiation-induced apoptosis (Piao et al., 2008). Concomitant inhi-
bition of K-ras increases the therapeutic effect of IGF-I receptor
antisense oligonucleotide (Shen et al., 2008). Human anti-IGF-I
receptor antibodies have been reported to enhance the anti-tumor
effects of gemcitabine and EGFR inhibition in vivo (Beltran et al.,
2009).
THE FOCAL ADHESION KINASE PATHWAY
Focal adhesion kinase (FADK) is a cytoplasmic non-receptor tyro-
sine kinase that mediates functions involved in cell motility and
survival and is closely related to the integrin signaling pathway.
Close to 80% of pancreatic cancers (Furuyama et al., 2006) express
FADKand, importantly, it shares a pathwaywith the IGF-I receptor
(Liu et al., 2008). The dual IGF-I receptor–FADK inhibitor NVP-
TAE226 has shown signiﬁcant tumor-suppressive activity in vivo
(Liu et al., 2007).
THE Src PATHWAY
Src is one of the nine members of the Src family of non-receptor
protein tyrosine kinases. In normal conditions, Src is maintained
in a phosphorylated and inactive form but it is activated in a
number of malignancies, including in 70% of pancreatic cancers
(Hakam et al., 2003). Src has diverse roles in cell proliferation,
survival, motility, invasiveness, resistance to chemotherapy, and
angiogenesis. This protein acts via multiple signaling pathways
and, therefore, is an ideal target for therapeutic intervention. Src
kinase inhibitors have been effective in suppressing pancreatic
tumor growth and metastasis in vivo (Baker et al., 2006; Trevino
et al., 2006; Ischenko et al., 2007). Dasatinib is an orally active
multitargeted kinase inhibitor of Src, BCR–ABL, platelet-derived
growth factor receptor (PDGFR), ephrin type A receptor 2, and
SCFR, and is licensed for the treatment of chronic myelogenous
leukemias and acute lymphoblastic leukemias. Dasatinib is being
examined in a phase II trial in patients with metastatic pancreatic
cancer (Morton et al., 2010).
THE Wnt PATHWAY
Wnt signaling is involved in normal embryonic development and
homeostatic self-renewal of a number of adult tissues. Three Wnt
signaling cascades have been described, the canonical Wnt–β-
catenin, the planar-cell polarity, and the Wnt–Ca2+ pathways.
The former is the best known and has been implicated in a vari-
ety of cancers including liver, colorectal, breast, prostate, renal,
and hematological malignancies. Normally, β-catenin is phospho-
rylated and targeted for degradation. However, binding of Wnt
proteins results in activation of intracellular pathways that cause
β-catenin to enter the nucleus, where its interaction with the T-
cell factor (TCF) and lymphoid enhancer factor (LEF) families of
transcription factors leads to targeted gene expression. Any gain-
of-function mutation of activators or loss-of-function mutation
of inhibitors of Wnt signaling could lead to aberrant activation
of these signaling pathways, which could result in carcinogenesis
and tumor progression. Aberrant activation occurs in 65% of pan-
creatic cancers (Zeng et al., 2006). Inhibition of Wnt signaling to
reduce proliferation and increase apoptosis of pancreatic cancer
cells has been achieved in the laboratory setting by a variety of
methods, including the use of β-catenin-interacting protein 1, a
dominant-negative mutant of LEF-1, and siRNA against β-catenin
or extracellular sulfatases (Nawroth et al., 2007; Pasca di Magliano
et al., 2007). Wnt signaling is positively regulated by the hedge-
hog and SMAD4 signaling pathways (Romero et al., 2008), which
could be targets for a combined inhibitory therapeutic strategy.
THE CHEMOKINE RECEPTOR 4 AND ITS LIGAND SDF-1
The chemokine receptor 4 (CXCR4) and its ligand, SDF-1 have a
role in tumor growth, angiogenesis, and particularly in metasta-
tic spread. In vitro blockade of CXCR4 inhibits pancreatic can-
cer growth through inhibition of the canonical Wnt pathway
(Wang et al., 2008). Furthermore, plerixafor, an antagonist of
CXCR4, reduces metastasis from pancreatic cancer cells positive
for the CXCR4 and CD133 markers (the latter being a marker of
pancreatic cancer stem cells) in vivo (Hermann et al., 2007).
OTHER ONCOGENES
Ampliﬁcation of other oncogenes also plays a very important
role in the development and progression of pancreatic cancer.
The Akt-2 gene is ampliﬁed in 15% of pancreatic cancers while
Myb gene is ampliﬁed in 10% of pancreatic cancers. The ampli-
ﬁcation of the oncogenes contributes to the stimulation of cell
growth and the progression of pancreatic cancers. There are exper-
imental evidences of up-regulation of other oncogenes including
Bcl-6, S100P, and Cyclin D1 (Mimeault et al., 2005). Up-regulation
of cyclin D1 has been found in pancreatic cancers and overex-
pression of cyclin D1 is associated with poor prognosis. Inhibit-
ing cyclin D1 in pancreatic cancer cell lines leads to growth
inhibition and loss of tumorigenicity in nude mice (Kornmann
et al., 1998). Recent studies have shown that overexpression of
cyclin D1 promotes tumor cell growth and confers resistance
to cisplatin-mediated apoptosis in an elastase–myc transgene-
expressing pancreatic tumor cell line, suggesting that cyclin D1
inﬂuences the progression of pancreatic cancer (Biliran et al.,
2005).
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INACTIVATION OF TUMOR SUPPRESSOR GENES
Inactivation of tumor suppressor genes is another important event
for the initiation of pancreatic cancer. Tumor suppressor genes
can be activated by mutation, deletion, or hypermethylation. The
tumor suppressor genes targeted in pancreatic cancer include p16,
p53, SMAD4, and PTEN (see Figure 1).
THE p16/INK4a PATHWAY
It has been shown that p16/INK4a inhibits the activity of cyclin D
and of the CDK4/6 complex. CDK4 and CDK6 normally interact
with cyclin D to phosphorylate the retinoblastoma (Rb) pro-
tein. The phosphorylation of Rb allows its dissociation from
a complex formed with the elongation factor 2 (E2F), allow-
ing E2F to activate genes required for DNA synthesis along the
cell cycle. p16/INK4a controls cell cycle progression through
G1/S transition by inhibiting cyclin D and CDK4/6 mediated
phosphorylation of Rb, and therefore inhibiting cell growth.
Approximately 95% of pancreatic cancer patients have inacti-
vated p16/INK4a in their tumors (about 40% by deletion, 40%
by mutation, and 15% by hypermethylation of its promoter;
Schutte et al., 1997). Experimental studies have demonstrated
that transfection of wild-type p16/INK4a into human pancreatic
cancer cells results in decreased tumor cell proliferation in vitro
and in vivo. Moreover, in pancreatic cancer patients the tumor
size is signiﬁcantly larger and the survival time is signiﬁcantly
shorter when the p16/INK4a mutation is present, compared to
patients with wild-type p16/INK4a. These evidences suggest that
p16/INK4a alterations participate in the aggressiveness of pancre-
atic cancer through its interaction with various cellular signaling
pathways.
THE p53 PATHWAY
In addition to p16/INK4a, another tumor suppressor gene, named
p53, is well known to be involved in the control of cell cycle.
p53 Binds to the p21/WAF1 promoter and stimulates the pro-
duction of p21/WAF1, which negatively regulates the complex
consisting of cyclin D1 and CDK2, thereby arresting the cell at the
G1 phase and inhibiting cell growth. The p53 also plays impor-
tant roles in the induction of apoptotic cell death. Inactivation of
p53 during carcinogenesis can lead to uncontrolled cell growth
and increased cell survival. The p53 gene is inactivated in about
50% of pancreatic cancers through gene mutation and deletion.
It had been shown that p53 mutation results in alteration of the
3D structure of the p53 protein (Li et al., 1998), associated with
shorter survival in patients with pancreatic cancer. In addition,
alterations in the p53 gene are associated with K-ras mutations,
suggesting a crosstalk and cooperative activity between p53 and
K-ras in the molecular pathogenesis of pancreatic cancers. More-
over, the status of p53 is important in mediating the speciﬁcity
of chemotherapeutic agents on cancers. Loss of p53 function
could result in decreased sensitivity to certain types of chemother-
apeutic agents. Therefore, the status of p53 could be a useful
guide for those patients who are likely to respond to adjuvant
chemotherapy.
THE TGF-β AND SMAD4 PATHWAY
TGF-β is a cytokine secreted by epithelial, endothelial, hematopoi-
etic, and mesenchymal cells. Binding of TGF-β to type I and type
II TGF-β receptors forms a heteromeric complex that triggers the
phosphorylation of cytoplasmic SMAD2 and SMAD3. In turn,
SMAD proteins form a complex with SMAD4, which translocates
into the nucleus to activate gene transcription. TGF-β can also sig-
nal via SMAD-independent pathways that involve Ras, PI3K, and
MAPK. TGF-β mediates a wide range of physiological processes,
such as embryonic development, tissue repair, angiogenesis, and
immunosuppression. TGF-β also has a complex role in tumorige-
nesis, as it is tumor-suppressive in epithelial cells, but promotes
invasion and metastasis during the late stages of cancer progres-
sion. Mutations of the TGFBR1 and TGFBR2 genes are found in
about 1 and 4% of pancreatic cancers, respectively (Goggins et al.,
1998b).
The inactivation of DPC4 (Deleted in Pancreatic Cancer locus
4, Smad4) tumor suppressor gene is another common genetic
alteration identiﬁed in pancreatic cancer. The DPC4 gene encodes
a 64-kDa protein, Smad 4, which plays roles in the inhibition of
cell growth and angiogenesis. The inactivation of DPC4 is rela-
tively speciﬁc to pancreatic cancer although it occurs with low
incidence in other cancers. It has been found that the DPC4
tumor suppressor gene is deleted in approximately 50% of pan-
creatic cancers (Cowgill and Muscarella, 2003). Up to 90% of
pancreatic adenocarcinomas could harbor loss of heterozygosity.
DPC4 alterations occur relatively late in pancreatic carcinogen-
esis. The frequency of loss of DPC4 expression is signiﬁcantly
higher in poorly differentiated pancreatic adenocarcinoma and
the pancreatic cancer patients with intact DPC4 gene have signif-
icantly longer survival after resection compared to patients with
mutant DPC4 gene. Furthermore, DPC4 inactivation is always
accompanied by inactivation of p16/INK4a, supporting its impor-
tance in the pathogenesis of pancreatic cancer. It is noteworthy
that inactivation of SMAD4 abolishes TGF-β-mediated tumor-
suppressive functions while it maintains some tumor-promoting
TGF-β responses, such as epithelial–mesenchymal transition,
which makes cells more invasive and more prone to migrate (Levy
and Hill, 2005).
TGF-β-based therapeutic strategies are currently in develop-
ment, including inhibitors of TGFBR1 and TGFBR2. AP 12009,
an antisense oligonucleotide speciﬁc to TGF-β2, is currently being
tested in a phase I–II study of malignant melanoma, pancreatic
cancer, and colorectal carcinomas (Bonafoux and Lee, 2009).
OTHER TUMOR SUPPRESSOR GENES
As indicated earlier, p21/WAF1 is an inhibitor of CDK. It forms
complexes with cyclinA/CDK2 or cyclinD1/CDK4 and inhibits
their activity, causing cell cycle arrest in G1 phase. Loss of
p21WAF1 activity has been observed in approximately 50% of
pancreatic cancers (Garcea et al., 2005). p27/CIP1 is another CDK
inhibitor which regulates cell cycle progression from G1 to S
phases. The loss of p27/CIP1 expression has also been observed in
pancreatic cancers (Garcea et al., 2005). Another tumor suppres-
sor gene, BRCA2, has been found to participate in DNA damage
repair and mutations in BRCA2 have been linked to a signiﬁcantly
increased risk of pancreatic cancer. These evidences demonstrate
that inactivation of p21/WAF1, p27/CIP1, and BRCA2 tumor
suppressor genes is involved in the pathogenesis of pancreatic
cancer.
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INTRACELLULAR SIGNALING PATHWAYS INVOLVED IN
PANCREATIC CANCER
THE EGFR SIGNALING
EGFR consists of an extracellular ligand-binding domain, a
hydrophobic transmembrane region, and an intracellular tyro-
sine kinase domain. EGFR is a member of the ErbB family of
receptor tyrosine kinases, which include ErbB-1 (EGFR), ErbB-
2 (HER-2), ErbB-3, and ErbB-4. The principal ligands of EGFR
are EGF and TGF-α. Binding of a ligand to EGFR induces recep-
tor dimerization, which results in intracellular transphosphory-
lation of tyrosine residues. Phosphorylation of EGFR activates
molecules in different cell signaling pathways including PI3K,
Src, MAPK, and STAT, inducing cell cycle progression, cell divi-
sion, survival, motility, invasion, and metastasis. The genomic
alterations of EGFR that occur in cancers include overexpres-
sion, mutation, deletion, and rearrangement. These alterations
of EGFR induce the activity of tyrosine kinase receptors and
may promote the development and progression of pancreatic
cancer. Experimental studies have shown that EGFR activation
plays important roles in proliferation, apoptosis inhibition, angio-
genesis, metastasis, and resistance to chemotherapy or radia-
tion therapy. Overexpression of EGF and EGFR is a common
feature of human pancreatic cancer (Talar-Wojnarowska and
Malecka-Panas, 2006). HER-2/neu ampliﬁcation and p185 over-
expression have been observed in more than 50% of pancreatic
cancers. Moreover, EGFR overexpression has been found sig-
niﬁcantly more often in advanced clinical stages of pancreatic
cancer and thus is associated with shorter survival in pancreatic
cancer patients (Talar-Wojnarowska and Malecka-Panas, 2006),
suggesting that deregulation of the EGFR pathway participates
in the development and progression of pancreatic cancer. The
EGFR signaling and its downstream signaling is therefore an
important signaling pathway to be targeted for pancreatic cancer
therapy.
Two classes of EGFR inhibitors, monoclonal antibodies, and
small molecule tyrosine kinase inhibitors have been considered in
the treatment of pancreatic cancer but results of comparative clin-
ical trials have been relatively disappointing (see above). Because
of the importance of EGFR in pancreatic cancer a novel negative
regulator of EGFR, termed EGFR-related protein (ERRP), whose
expression was found to attenuate EGFR activation was devel-
oped. ERRP signiﬁcantly inhibits cell proliferation and induces
apoptosis in BxPC3, HPAC, and Panc1 pancreatic cancer cells
(Zhang et al., 2005, 2006). ERRP also inhibits ligand-induced acti-
vation of EGFR, HER-2, and HER-3. Most importantly, ERRP
was found to inhibit pancreatic tumor growth in a SCID mouse
xenograft model. The anti-tumor activity of ERRP correlated
well with down-regulation of NFκB, MAPK, Akt, and Notch-
1 (Zhang et al., 2005, 2006; Wang et al., 2006b). ERRP also
down-regulates genes downstream from NFκB such as vascular
endothelial growth factor (VEGF) and MMP-9, and inhibits can-
cer cell invasion, suggesting that ERRP could be a very potent
agent for the treatment of pancreatic cancer by inhibiting cell sur-
vival signaling, tumor growth, invasion, and angiogenesis. These
results suggest that further development of ERRP for clinical use
is mandatory.
THE Akt SIGNALING
EGF binding and subsequent EGFR, ras, or Src activation lead to
the activation of the PI3K pathway.Activated PI3K phosphorylates
phosphatidylinositides (PIP3), which eventually phosphorylate
and activate Akt which in turn has multiple downstream tar-
gets, including the mammalian target of rapamycin (mTOR) and
the transcription factor NFκB. Phosphorylated Akt (p-Akt) pro-
motes cell survival by inhibiting apoptosis and activating NFκB.
p-Akt is known to inhibit apoptosis through its ability to phos-
phorylate and inactivate several targets including Bad, Forkhead
transcription factors, and caspase-9, all of which are involved in
the apoptotic pathway. Akt also regulates the NFκB pathway via
phosphorylation and activation of molecules in the NFκB path-
way, suggesting that there is a cross talk between these two signaling
pathways. AKT2 is ampliﬁed and the PI3K–Akt pathway is acti-
vated in 20 and 60% of pancreatic cancers, respectively (Ruggeri
et al., 1998; Schlieman et al., 2003). Deregulation of this pathway
through aberrant expression of PTEN (phosphatase and tensin
homolog, a natural antagonist of PI3K) is frequently observed in
pancreatic cancer (Asano et al., 2004). Furthermore, an architec-
tural transcription factor, HMGA1, is overexpressed in pancreatic
cancer (Abe et al., 2000). This transcription factor activates PI3K–
Akt signaling and seems tomediate resistance to gemcitabine (Liau
and Whang, 2008), which, therefore, provides another target for
inhibition therapy (Trapasso et al., 2004; Liau et al., 2006). Fur-
thermore, the inhibition of Akt decreases the function of NFκB,
and has been shown to sensitize MiaPaCa2 pancreatic cancer cells
to chemotherapy (Fahy et al., 2004), suggesting that both Akt and
NFκB are potential targets for the treatment of pancreatic cancers.
Temsirolimus is an mTOR inhibitor approved for the treat-
ment of renal-cell carcinoma, but use of this agent in pancreatic
cancer has been limited. Other agents, including everolimus and
sirolimus, are currently in phase II clinical trials (Wolpin et al.,
2009). A combination of an mTOR inhibitor with other standard
or targeted therapies might be needed, as mTOR expression does
not correlate with survival of patients.
THE NFκB SIGNALING
The NFκB signaling pathway plays important roles in the con-
trol of cell growth, differentiation, apoptosis, inﬂammation, stress
response, and many other physiological processes in cellular sig-
naling (Karin, 2006). In human cells without speciﬁc signal, NFκB
is sequestered in the cytoplasm through tight association with its
inhibitors: IκBαwhich acts as anNFκB inhibitor andp100 proteins
which serves as both an inhibitor and precursor of NFκB DNA-
binding subunits.NFκB can be activated through phosphorylation
of IκBα by IKKβ and/or phosphorylation of p100 by IKKα, leading
to degradationof IκBα and/or the processing of p100 into a smaller
form (p52). This process allows two forms of NFκB (p50–p65 and
p52–RelB) to become free, resulting in the translocation of active
NFκB into the nucleus for binding to NFκB-speciﬁc DNA-binding
sites and, in turn, regulating gene transcription. By binding to the
promoters of target genes, NFκB controls the expression of many
genes [i.e., survivin, MMP-9, urokinase-type plasminogen activa-
tor (Upa), and VEGF] that are involved in cell survival, apoptosis,
invasion, metastasis, and angiogenesis.
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NFκB is constitutively activated inmost human pancreatic can-
cer tissues and cell lines but not in normal pancreatic tissues and
cells, suggesting that the activation of NFκB is involved in the car-
cinogenesis of pancreas. Inhibition of NFκB by a super-inhibitor
of NFκB results in impaired proliferation and induction of apop-
tosis (Liptay et al., 2003), suggesting an important role of NFκB
in pancreatic tumorigenesis. Moreover, the inhibition of consti-
tutive NFκB activity completely suppresses metastasis in liver of
the pancreatic cancer cell line ASPC1 (Fujioka et al., 2003). An
experimental study also demonstrates that uPA, one of the critical
proteases involved in tumor invasion and metastasis, is overex-
pressed in pancreatic cancer cells, and its overexpression is induced
by constitutive NFκB activity (Wang et al., 1999). These results
suggest that constitutively activated NFκB is tightly related to the
invasion and metastasis frequently observed in pancreatic cancers.
Moreover, thederegulationof NFκBcould alsobedue toNotch sig-
naling as discussed earlier and as such the crosstalk between Notch
andNFκBappears tobe an important signaling event that regulates
the processes of tumor invasion and angiogenesis in pancreatic
cancer.
De novo resistance to chemotherapeutic agents is a major
cause of treatment failure in pancreatic cancer, which could
be due to the constitutive activation of NFκB among others.
Moreover, chemotherapeutic agents can activate NFκB in pan-
creatic and other cancer cells, leading to cancer cell resistance to
chemotherapy (acquired resistance). Therefore, the strategies by
which NFκB could be inactivated represent a novel approach for
the treatment of pancreatic cancer. Some studies have demon-
strated that the anti-tumor effects of chemotherapeutic agents
can be enhanced by combination treatment involving inhibi-
tion of NFκB. It was shown that NFκB activity was signiﬁcantly
increased by cisplatin, docetaxel, doxorubicin, and gemcitabine
treatment. When the NFκB inducing activity of these agents was
completely abrogated by pre-treatment of the pancreatic cancer
cells with NFκB inhibitors, growth inhibition, and apoptosis were
clearly enhanced (Muerkoster et al., 2003; Zhang et al., 2003; Li
et al., 2004b, 2005; Banerjee et al., 2005; Mohammad et al., 2006).
Recently, it was also shown that anti-tumor and anti-metastatic
activities of docetaxel could be enhanced by NFκB inhibitors
through regulation of osteoprotegerin/receptor activator of NFκB
(RANK)/RANK ligand/MMP-9 signaling in vitro and in vivo (Li
et al., 2006).
THE GASTRIN AND CHOLECYSTOKININ RECEPTORS
The peptide hormone gastrin is secreted by G cells in the gas-
tric antrum and duodenum and it can act as a growth factor
for gastric, colonic, and pancreatic cancers. CCK-BR (the gas-
trin and cholecystokinin receptor), gastrin precursors, and the
fully amidated gastrin are expressed in 95, 55–91, and 23% of
pancreatic cancers, respectively (Caplin et al., 2000). A selective
CCK-BR antagonist, gastrazole, was tested in two small, random-
ized, controlled trials in patients with advanced pancreatic cancer
(Chau et al., 2006). Gastrazole was superior to placebo, but not
to 5-ﬂuorouracil. Another inhibitor, the orally active Z-360, has
demonstrated promising laboratory results and, in combination
with gemcitabine, is well-tolerated by patients (Kawasaki et al.,
2008). An alternative approach to a blockade of this pathway
involves the use of gastrimmune, an immunogen that stimu-
lates the formation of antibodies against gastrin 17 and its pre-
cursors. This agent was, however, not successful in a phase III
trial.
THE HEDGEHOG SIGNALING
Hedgehog (Hh) signaling is an essential pathway for embryonic
pancreatic development. Hh signaling plays important roles in
adequate tissue morphogenesis and organ formation during gas-
trointestinal tract development. Hedgehog ligands including sonic
hedgehog (Shh) are expressed throughout the endodermal epithe-
lium at early embryonic stages but excluded from the region that
forms the pancreas. Deregulation of the Hh pathway has been
implicated in a variety of cancers including pancreatic cancer.
Overexpression of Shh was reported to contribute to pancre-
atic tumorigenesis. Thayer et al. (2003) found that no Shh was
detected in the islets, acini, or ductal epithelium of normal pan-
creas while Shh was aberrantly expressed in 70% of specimens
from patients with pancreatic adenocarcinoma, suggesting that
Shh is amediator of pancreatic cancer tumorigenesis. Importantly,
the down-regulation of Shh by cyclopamine, a speciﬁc inhibitor
of Shh, can reduce the growth and viability of pancreatic cancer
cells, suggesting that targeting Shh signaling may be an effective
novel approach for the treatment of pancreatic cancer (Berman
et al., 2003). Cyclopamine can enhance sensitivity to radiother-
apy and chemotherapy and suppress metastatic spread (Shafaee
et al., 2006; Feldmann et al., 2007) as well as improving anti-
tumor activity when combined with an EGFR inhibitor (Hu et al.,
2007). A downstream target of the Shh pathway, the transcrip-
tion factor GLI 1, can also be inhibited by miRNA (Tsuda et al.,
2006).
A recent report shows that NFκB contributes to Hh signaling
pathway activation through Shh induction in pancreatic cancer
(Nakashima et al., 2006), demonstrating a crosstalk between NFκB
and Hh signaling pathways in pancreatic cancer.
OTHER MECHANISMS INVOLVED IN THE PATHOGENESIS OF
PANCREATIC CANCER
INFLAMMATION
There is a growing feeling that inﬂammation contributes to
pancreatic cancer development. The initiation, promotion, and
progression of tumors may be inﬂuenced by numerous compo-
nents including cytokines such as TNF-α, IL-6, IL-8 and inter-
feron γ, the COX-2, and the peroxisome proliferator-activated
receptor-γ, that function in the inﬂammatory response. Other
mechanisms involved in the inﬂammatory response may also
contribute to neoplasia, such as free radicals which may partic-
ularly contribute to cancer initiation. Free radicals can induce
genetic alterations and post-translational modiﬁcations of key
cancer-related proteins. Reactive oxygen intermediates and reac-
tive nitrogen intermediates are capable of causing oxidative dam-
age and nitration of DNA bases, thus increasing the likelihood
that DNA mutations occur (Hussain et al., 2003). Interestingly,
recognized risk factors for pancreatic cancer such as cigaret
smoking, chronic hereditary pancreatitis, obesity, and type II
diabetes are linked by the fact that inﬂammation signiﬁcantly
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drives these pathologies. By itself, chronic pancreatitis is associ-
ated with increased risk of pancreatic cancer while obesity and
cigaret smoking require additional co-factors to induce pancre-
atic carcinogenesis. The role of inﬂammation in the promotion
of pancreatic cancer from PanIN lesions has been experimen-
tally conﬁrmed by Guerra et al. (2007, 2011) using an elegant
mutated K-ras-dependent mouse model in which the animals
develop PanIN lesions spontaneously. In these works, repeated
episodes of caerulein-induced acute pancreatitis are able to pro-
mote cell transformation, apparently by blocking the mutated
K-ras-induced senescence. Activation of STAT3 in pancreas cancer
is related to tumor growth directly through mechanisms affect-
ing the tumor and indirectly by modulating tumor-associated
stroma and the immune system. Activation depends on the phos-
phorylation of a conserved tyrosine residue (Y705) by upstream
kinases, such as Janus kinase 2 (Jak2). Jak2 activation requires
activation of the ubiquitously expressed gp130 receptor by spe-
ciﬁc ligands (IL-6, LIF, IL-11, oncostatin M, CNTF, and IL-27).
Importantly, it was recently reported that STAT3 activity plays a
critical role in K-ras-induced pancreatic tumorigenesis (Corcoran
et al., 2011) supporting the link between STAT3 activation and cell
transformation (Figure 2).
THE TELOMERASES
The telomeres located at the end of chromosomes normally shrink
with each cell division and thereby impose a ﬁnite lifespan to
the cell. Most malignant cells have detectable activity of telom-
erase, a reverse transcriptase that contains an RNA template and
elongates telomeres. Telomerase is overexpressed in 95% of pan-
creatic cancers (Hiyama et al., 1997) which provides a rationale
for the development of antitelomerase agents. GV1001 is a telom-
erase peptide vaccine that has shown some promising results in
phase I/II studies (Bernhardt et al., 2006). This vaccine is being
tested in the large (>1000 patients), phase III, TeloVac trial with
FIGURE 2 | Mechanisms involved in pancreas cancer. At the upper part,
in red, are shown the mechanisms that promote pancreatic cancer, and at
the lower part, in green, are showed the mechanisms against pancreatic
cancer development.
gemcitabine and capecitabine in locally advanced and metastatic
pancreatic cancers (Figure 2).
ANGIOGENESIS
Angiogenesis is essential for solid tumor growth, and is princi-
pally mediated by the VEGF family of proteins and receptors.
Stimuli that upregulate VEGF expression include hypoxia, other
growth factors, and oncogenic proteins such as TGF-β, EGF, and
Ras. VEGF is overexpressed in >90% of pancreatic cancers (Seo
et al., 2000) and is, therefore, an appealing target for therapy.
Bevacizumab is a humanized antibody against VEGF approved
for use in patients with colorectal cancer. However, a phase III trial
in advanced pancreatic cancer failed to show any survival ben-
eﬁt for bevacizumab in combination with gemcitabine (Kindler
et al., 2010). The AVITA (BO17706) phase III study of patients
with metastatic pancreatic cancer reported that the addition of
bevacizumab to gemcitabine and erlotinib did not signiﬁcantly
prolong overall survival, although a signiﬁcant improvement in
progression-free survival was seen (Van Cutsem et al., 2009). A
number of other trials are being conducted to examine beva-
cizumab in combinationwith other agents or treatmentmodalities
for pancreatic cancer; however, this agent seems unlikely to con-
fer sufﬁcient beneﬁt to justify its licensing for this condition. The
failure of bevacizumab in therapeutic trials for pancreatic cancer
highlighted the need for angiogenic inhibitors that could target
other non-VEGF pathways and have better access to the tumor
environment than an antibody. Sorafenib is a multitargeted kinase
inhibitor that inhibits theVEGF receptor (VEGFR),PDGFR,SCFR
(formerly c-KIT), Raf1, and FLT3, which are all implicated in
tumor growth and angiogenesis. Sorafenib was approved in 2005
for the treatment of advanced renal-cell carcinoma. However, a
phase II study concluded that, although well-tolerated, it was
inactive in patients with advanced pancreatic cancer. A random-
ized phase III study comparing gemcitabine plus sorafenib versus
gemcitabine plus placebo was recently reported and revealed no
advantage for the experimental arm (Gonçalves et al., 2011). Axi-
tinib is an orally active inhibitor of both VEGFR and related tyro-
sine kinase receptors at high concentrations. A median survival of
6.9months was reported for axitinib combined with gemcitabine
compared with 5.6months for gemcitabine alone in a phase II
trial in patients with advanced pancreatic cancer, but this ﬁnding
was not statistically signiﬁcant (Spano et al., 2008). Phase III trials
of axitinib combined with gemcitabine are currently in progress.
Aﬂibercept, a recombinant fusion protein that functions as a solu-
ble decoy receptor and thereby inhibits VEGF, is another novel
agent being tested in a phase III trial of patients treated with
gemcitabine for metastatic pancreatic cancer (Figure 2).
SIGNALING BY INTEGRIN RECEPTORS
Integrin receptors on the cell surface interact with the extracellular
matrix and mediate various signaling pathways. These receptors
are involved in many neoplastic processes, including tumor sur-
vival, invasion, and metastasis. The αVβ3 and αVβ5 integrins
induce angiogenesis, principally via basic ﬁbroblast growth fac-
tor and VEGF, respectively. Cilengitide inhibits these integrins,
but in a phase II trial in patients with advanced pancreatic can-
cer it did not show signiﬁcant beneﬁt compared to gemcitabine
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alone (Friess et al., 2006). Other anti-integrin agents, including
an antibody against α5β1 (volociximab; Ricart et al., 2008) and an
inhibitor of α2 (E7820) are in early phase clinical trials (Funahashi
et al., 2002; Figure 2).
MATRIX METALLOPROTEINASES
Matrixmetalloproteinases (MMPs) are a family of zinc-dependent
proteolytic enzymes that degrade the extracellular matrix and are
essential for tumor spread and neovascularization. We should not,
therefore, be surprised that imbalance between MMPs and their
natural inhibitors is a frequent event in pancreatic cancer. Despite
promising laboratory results,MMP inhibitors have failed to live up
to their initial therapeutic expectation in three phase III clinical tri-
als (Bramhall et al., 2001, 2002;Moore et al., 2003), although critics
argued that the trials included a large number of patients with
metastatic disease, which contradicts the rationale of exploiting
the cytostatic effect of MMP inhibitors (Figure 2).
CANCER STEM CELLS
Cancer stem cells possess important properties associated with
their normal counterparts, namely the ability for self-renewal and
differentiation. Pancreatic cancer stem cells are identiﬁed by their
surface markers, such as CD133, CD44, CD24, and ﬂotillin 2
epithelial speciﬁc-antigen. Evidence suggests that such cells form
a small subset in the heterogenous tumor population, and con-
tribute to neoplastic progression, metastasis, and resistance to
chemotherapy and radiotherapy (Hermann et al., 2007; Lee et al.,
2008). For this reason, cancer stem cells are thought to be respon-
sible for relapse of disease after clinical remission. Dysregulation
of various signaling cascades, including the PTEN, Shh, Notch,
and Wnt pathways, are frequently observed in cancer stem cells,
which provides further rationale for use of these pathways as a
target for therapeutic purposes. Further studies are still needed to
understand the genetic and biological properties of cancer stem
cells for the development of effective treatment modalities.
miRNA EXPRESSION PROFILING IN PANCREATIC DUCTAL
ADENOCARCINOMA
Analysis of miRNA expression in PDAC revealed a speciﬁc miRNA
signature that can be monitored by proﬁling miRNAs at different
stages of cancer (Table 1). Over the past years, a number of dif-
ferent approaches, including DNA microchips and RT-PCR have
been described to quantify miRNAs. By these techniques, several
studies demonstrated the tissue-speciﬁcity of miRNA expression
and the deregulation of miRNA expression in pancreatic cancer
Table 1 | Genes implicated in the familiar forms of pancreas cancer.
Hereditary breast and
ovarian cancer syndrome
BRCA1 and BRCA2
Peutz–Jeghers syndrome LKB1
Hereditary chronic pancreatitis PRSS1 and SPINK1
Hereditary non-polyposis colorectal
cancer syndrome
hMSH2, hMLH1, hPMS1,
hPMS2, and hMSH6
Familial atypical multiple mole melanoma CDKN2A/p16
Familial adenomatous polyposis APC
(Roldo et al., 2006; Szafranska et al., 2007). Monitoring differ-
ential miRNA expression might therefore be useful in the differ-
ential diagnosis of pancreatic cancer. Expression of the miR-376
precursor was highest in the human pancreatic cancer cell line
Panc1, compared to other cell lines studied (Jiang et al., 2005;
Volinia et al., 2006). Large-scale miRNA proﬁling in 540 sam-
ples of solid tumors (breast, colon, lung, pancreas, prostate, and
stomach) showed that the spectrum of miRNA expression varied
in different solid tumors and was different from that of normal
cells (43 of 137 miRNAs, 31%). miR-21, miR-191, and miR-17-5p
were signiﬁcantly overexpressed in all six tumor types, whereas
miR-218-2 was consistently down-regulated in colon, stomach,
prostate, and pancreatic cancers, but not in lung and breast carci-
nomas. This observation indicates that colon, pancreas, prostate,
and stomach have similar miRNA signatures, different from those
of breast and lung cancer. Similarly, up-regulation of miR-142-3p,
miR-142-5p, miR-155, and miR-146a expressions was observed
in human pancreatic neuroendocrine tumors (PNETs) as com-
pared with normal human islets (Olson et al., 2009). Lee et al.
(2007) reported the aberrant expression of 100 miRNA precur-
sors in pancreatic cancer or desmoplasia, including the miRNAs
previously reported in other human cancers (miR-155, miR-21,
miR-221, and miR-222) as well as the ﬁrst reported miR-376a and
miR-301 for the differential expression of cancer. A signiﬁcant up-
regulation of miR-196a, miR-190, miR-186, miR-221, miR-222,
miR-200b,miR-15b, and miR-95 in most pancreatic cancer tissues
and cell lines was reported. miR-155 and miR-21 were signiﬁ-
cantly up-regulated in 15 IPMNs versus matched controls (Habbe
et al., 2009). miR-155 was up-regulated in 53 of 64 IPMNs (83%)
compared to 4 of 54 normal ducts only (7%), and miR-21 was
up-regulated in 52 of 64 IPMNs (81%) compared to 1 of 54 nor-
mal ducts (2%). The expression of miR-216 has also shown to
be speciﬁc to the pancreas (Sood et al., 2006). Let-7 miRNA was
found expressed in pancreatic cancer cells but did not inhibit the
epithelial–mesenchymal transition (Watanabe et al., 2009). There-
fore,miRNAs play vital roles not only in different kinds and stages
of pancreatic tumors but also in many diseases, including can-
cers, cardiovascular diseases, and immune disorders. Epigenetic
modiﬁcations, DNA copy number changes, and genetic mutations
may regulate the expression of miRNAs. The conclusion of these
data is that PDAC miRNAomes associated with normal and tumor
tissues are different. Differences are tumor-speciﬁc and, in some
cases, indicators of prognosis. These ﬁndings suggest that miRNA
expression patterns constitute a signature of the disease which
could offer new clues about pancreatic cancer occurrence and also
provide new molecular markers that would improve diagnosis and
orient the treatment. A very promising diagnostic strategy could
arise from miRNAs if they are found in serum and can be detected
by RT-PCR. In a remarkable study Lu et al. (2005) showed that
expression data for 217 miRNAs only performed better at identi-
fying cancer types than analysis of 16000 mRNAs. They concluded
that miRNAs might help detecting cancer better than other strate-
gies presently available because miRNAs are only several hundred,
compared to tens of thousands for mRNAs and proteins. One sin-
gle miRNA can modulate the expression of many genes rendering
miRNAs powerful molecules regulating several related pathways,
each miRNA playing multiple but coherent roles in the cell.
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EPIGENETICS OF PANCREATIC CANCER
The revolution of somatic genetics in the ﬁeld of cancer brought
about by the model developed by Fearon and Vogelstein (1990) in
colon, which later led to an adaptation to the pancreas by Hruban
et al. (2000), opened a fruitful era for pancreatic cancer research.
The basic premise of somatic genetics in cancer is that if a gene,
which is suspected to play a role related to cancer, is over-ampliﬁed
ormutatedwith gain-of-function, it behaves as an oncogene, but if
it is deleted ormutatedwith loss-of-function, it behaves as a tumor
suppressor.However, in light of themodernbiologywe can assume
that regulation of genes activity is more complex and it is there-
fore necessary to explain how changes in chromatin dynamics can
silence tumor suppressor genes via mechanisms that are totally
independent from either deletions or mutations of these genes.
Some epigenetic mechanisms can silence gene function such as:
DNA METHYLATION
DNA methylation was the ﬁrst type of epigenetic change to be
studied as a mechanism for the inactivation of tumor suppres-
sors (Esteller, 2008). DNA methylation occurs on dinucleotide
CpGs. The process of DNA methylation entails the addition of a
methyl group to carbon number 5 of the cytosine pyrimidine ring,
which ultimately silences gene expression. In pancreatic cancer,
DNA methylation has been known for a long time as a mech-
anism for inactivating tumor suppressor genes, a well known
example being the inactivation of the p16 promoter via methy-
lation (Singh and Maitra, 2007). In addition, loss of methylation
of a normally silenced promoter in pancreatic cells, such as in
the gene encoding the hematopoietic-speciﬁc guanine nucleotide
exchange factor, VAV1, can alter its expression (Fernandez-Zapico
et al., 2005). Although several genes were discovered to be methy-
lated in advanced pancreatic cancer, current evidence supports
the idea that aberrant methylation occurs very early during the
histopathological progression of this neoplasia. Interestingly, in
a study involving large-scale methylation analysis, Sato et al.
(2003) analyzed DNA samples from 65 PanIN lesions for methy-
lation status of eight genes, identiﬁed beforehand by a large-scale
microarray approach as aberrantly hypermethylated in invasive
pancreatic cancer.Methylationof these geneswas identiﬁed in 68%
of PanINs. More importantly, aberrant methylation was present in
approximately 70% of PanINs-1A, the earliest lesions. The preva-
lence of methylation increased from PanIN-1 to PanIN-2 for the
NPTX2 gene, and from PanIN-2 to PanIN-3 for SARP2, Reprimo,
and LHX1.
HISTONE ACETYLATION AND DEACETYLATION
Another important mechanism underlying the epigenetic reg-
ulation of gene expression is the acetylation and deacetylation
of lysine residues within histone tails. Regarding acetylation, the
process occurs via HATs, such as CBP, P300, and PCAF, to result in
activation of gene expression, whereas deacetylation is mediated
by two different families of HDACs, resulting in gene silenc-
ing. Together, these enzymes provide a ﬁne-tuned mechanism
which, upon alteration, can promote the activation of oncogenic
pathways and the silencing of tumor suppressors. Studies have
demonstrated that HDAC activity is increased in various tumors
compared with normal tissue, and this increase in HDAC activity
has been associated with transcriptional repression of tumor sup-
pressor genes that cause growth inhibition and apoptosis (Cress
and Seto, 2000). In a study performed by Ouaïssi et al. (2008)
∼80% of pancreatic adenocarcinoma samples examined showed
a signiﬁcant increase in HDAC7 RNA and protein levels (Ouaïssi
et al., 2008). Thus, it is clear that HDACs play an important role
in the maintenance of the proper balance of chromatin marks on
a given promoter. If this balance is altered, such as with HDAC
overexpression in pancreatic cancer, the expected global effect on
promoters is daunting.
HISTONE H3–METHYL-K27 AND POLYCOMB
Polycomb proteins silence gene expression by speciﬁcally methy-
lating histone H3, on K27 (Cao et al., 2002; Ringrose, 2007). At the
core of this pathway, the polycomb group of proteins (PcG) act
via the stepwise recruitment of PRC2, containing the histone H3
K27 methylase activity, to chromatin. Subsequently, the trimethyl-
K27–H3 mark deposited by PRC2 recruits the PRC1 complex,
thereby completing the formation of the gene silencing complex.
The enzymatic activity of the PCR2 complex involves the K27–H3
histone methylase, EZH2, but requires formation of a complex
with Suz12 and EED to function. The PCR1 complex contains
the oncogene BMI1, as well as HPC1-3, HPH1-3, SCMH1, and
the methyl-K27–H3-binding proteins, Cbx 2, 4, 6, 7, and 8. The
role of polycomb proteins in pancreatic cancer is an emerging
area of research. Interesting studies have demonstrated that loss
of trimethylation at lysine 27 of histone H3, which is achieved by
EZH2, is a predictor of poor outcome in pancreatic cancers (Wei
et al., 2008). In fact, together with tumor size and lymph node sta-
tus, the level of trimethyl-K27–H3 was found to have a strong and
independent prognostic inﬂuence in pancreatic cancer. In another
recent study, nuclear accumulation of EZH2 was identiﬁed as a
hallmark of poorly differentiated pancreatic adenocarcinoma and
nuclear overexpression of EZH2 contributes to pancreatic can-
cer cell proliferation, suggesting EZH2 as a potential therapeutic
target for the treatment of pancreatic cancer (Ougolkov et al.,
2008). Mechanistically, one of the outcomes of aberrant poly-
comb regulation is the silencing of the p16 gene, which could
occur prior to DNA methylation, directly via altered recruitment
of members of this family to the p16 promoter sequence (Kotake
et al., 2007). Upon recent studies in human cells, EZH2, and DNA
methyltransferases (DNMTs) were found to physically and func-
tionally interact, evidenced by the PRC2 subunits, EZH2, and
EED, co-immunoprecipitating with all three human DNMTs and
the co-dependency of certain target gene silencing requiring both
EZH2 and DNMTs (Vire et al., 2006). Therefore, the presence of
polycomb proteins on the p16 promoter can recruit DNA methy-
lases which then further inactivate the expression of p16 via DNA
methylation.
HISTONE H3–METHYL-K9 AND HETEROCHROMATIN PROTEIN 1
HP1 binds to methylated K9 of histone H3, causing transcrip-
tional repression (Lomberk et al., 2006). This occurs through
the N-terminal chromodomain of HP1, while the highly related
C-terminal chromo shadow domain allows for dimerization of
these HP1 molecules and serves as a docking site for various fac-
tors involved in a wide array of functions, from transcription to
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maintaining nuclear architecture. To mediate gene silencing via
the formation of heterochromatin, HP1 isoforms must interact
with two different H3–K9 histone methylases namely G9a and
Suv39h1 (Lomberk et al., 2006). These methylases work in con-
cert with HP1 in a circular manner to form silenced chromatin.
When either of the methylases adds methyl groups to K9, this, in
turn, forms an HP1 docking site on chromatin. Since HP1 also
recruits the methylases, this cycle repeats, and the HP1-methylase
pair can spread the formation of silenced chromatin to adjacent
nucleosomes, causing long-term silencing of entire genes.
EPIGENETICS AS TARGET FOR CHEMOPREVENTION AND
CHEMOTHERAPIES
The study of epigenetics also impacts the ﬁeld of therapeu-
tics. In stark contrast with genetic alterations, epigenetic changes
have been proven to be reversible. For instance, methylation
can be reversed through the use of 5-Aza-2′-Deoxycytidine or
DNA methyltransferase inhibitors. Two types of DNMT inhibitors
exist, namely, nucleoside and non-nucleoside (small molecule)
inhibitors (Mund et al., 2006; Grifﬁths and Gore, 2008). These
types of pharmacologic DNMT inhibitors are currently being
tested in phase I–III clinical trials. Currently, among the most
promising epigenetic treatments for cancer are the potential ther-
apeutic agents that target histone deacetylation HDAC inhibitors
(HDACIs; Berger, 2002; Glaser et al., 2003; Bruserud et al., 2007;
Hildmann et al., 2007; Pan et al., 2007). Intuitively, the proposed
mechanisms of action for HDACs attempt to harness their ability
to reactivate transcription of multiple genes found to be silenced
in human tumors. However, their pleiotropic anti-tumor effects,
speciﬁc for cancer cells, along with their potential activity in other
diseases, elicits the possibility that they also act in other biolog-
ical processes, currently poorly understood. In addition to being
well-tolerated, several HDACIs show promising anti-tumor activ-
ity with more than 50 naturally occurring or synthetic HDACIs
currently developed. Hydroxamic acid compounds, trichostatin A
(TSA), and suberoylanilide hydroxamic acid (SAHA), are the best
known among these agents. By the same token, however, other
equally promising, although less known, drugs can be classiﬁed
into wider groups such as short-chain fatty acids (e.g., valproic
acid), epoxides (e.g., trapoxin), cyclic peptides (e.g., apicidin),ben-
zamides (e.g., CI-994, Nacetyldinaline), and hybrid compounds
(e.g., SK-7068). Recent studies have shown that certain HDACIs
can induce death of cultured pancreatic cells (Ouaïssi et al., 2008).
Additionally, conventional chemotherapeutic drugs, such as gem-
citabine, in combination of some of these agents, can achieve a
synergistic inhibition of pancreatic adenocarcinoma cell growth
(Donadelli et al., 2007). As a result of these promising studies, new
agents belonging to this family of drugs, such as FR235222, could
potentially be used as therapeutic tools in this cancer (Singh et al.,
2008). HDACIs are in advanced phases of clinical trials and may
soon become part of the therapeutic regimen for oncologists treat-
ing this disease. It is interesting to note that HDACIs are already
potential therapeutic agents against pancreatic cancer, in spite of
the fact that the characterization of histone deacetylases in pancre-
atic cancer is far from being completed and their role is not fully
understood.
GENETICS OF THE FAMILIAL PANCREATIC
ADENOCARCINOMA
In addition to sporadic adenocarcinoma, an increased risk of pan-
creatic cancer has been demonstrated among personswith a family
history of pancreatic cancer. Coughlin et al. (2000) reported an
increased risk of developing pancreatic cancer for individuals who
reported a positive family history of pancreatic cancer at baseline,
with a relative risk of 1.5 after adjustment for age. Furthermore,
a population-based cohort study demonstrated that the risk of
pancreatic cancer increased 1.72-fold for individuals with a par-
ent who developed a pancreatic cancer. The risk was not elevated
when a more distant relative had been diagnosed with pancre-
atic cancer. Thus, several studies strongly support the hypothesis
that familial aggregation and genetic susceptibility play an impor-
tant role in the development of pancreatic cancer. Discovering the
genetic basis of inherited pancreatic cancer is an active area of
research. In 2001, a multicenter linkage consortium, PACGENE,
was established to conduct linkage studies aiming at localizing
and identifying pancreatic cancer susceptibility genes (Petersen
et al., 2006). Other groups have used linkage studies to suggest
that mutations in the paladin gene (PALD) on chromosome 4q32
predisposes to pancreatic cancer (Pogue-Geile et al., 2006); how-
ever, this ﬁnding has not been validated in subsequent studies (Earl
et al., 2006). The complex nature of pedigree data makes it difﬁ-
cult to accurately assess risk based upon the simple counting of
the number of affected family members, as it does not account
for family size, current age, or age of onset of pancreatic can-
cer, and the exact relationship between affected family members.
Computer-based, risk assessment tools have been developed to
integrate this complex risk factor andpedigree data into risk assess-
ment. Thesemodels can providemore precise risk assessment than
guidelines or models that rely on counts of affected family mem-
bers, such as the Bethesda Guidelines for hereditary non-polyposis
colorectal cancer (HNPCC) or myriad tables for hereditary breast
and ovarian cancer. In April 2007, the ﬁrst risk prediction tool
for pancreatic cancer, PancPRO, was released (Wang et al., 2007).
Although the genetic basis for most instances of aggregation of
pancreatic cancer in families is unknown, the genes responsible for
a small portion of familial pancreatic cancer are known (Table 2).
Germline mutations in the BRCA2, CDKN2A/p16, STK11/LKB1,
andPRSS1 genes have all been shown to increase the risk of pancre-
atic cancer (Lowenfels et al., 1993;Goldstein et al., 1995;Whitcomb
et al., 1996; Giardiello et al., 2000). Additionally, some studies have
described pancreatic cancers developing among individuals with
HNPCC; however, the association between HNPCC syndromes
and pancreatic cancer is not as well-deﬁned as it is for some of the
other syndromes (Abraham et al., 2001; Yamamoto et al., 2001).
While most patients with sporadic and familial pancreatic cancer
have classic inﬁltrating ductal (tubular) adenocarcinoma, some
inherited syndromes are associated with a speciﬁc histologic type.
Although rare, these cases provide a unique opportunity to corre-
late genetics with histology. For example,many pancreatic cancers
that develop in patients with HNPCC syndrome have a medullary
phenotype (Goggins et al., 1998a; Wilentz et al., 2000; Banville
et al., 2006) and individuals with the Peutz–Jeghers syndrome
appear to be predisposed to IPMNs (Su et al., 1999; Furukawa,
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Table 2 | microRNAs frequently misregulated in pancreatic cancers.
Up Down
miR-155 miR-375
miR-100 miR-345
miR-376a miR-142-P
miR-125b-1 miR-139
miR-181a miR-148a
miR-181c miR-148b
miR-146a miR-141
miR-196a miR-96
miR-25 miR-29c
miR-214 miR-130b
miR-222 miR-216
miR-29b-2 miR-217
miR-128b miR-107
miR-200 miR-34a
miR-95 Let-7
miR-15b miR-218-2
miR-32
miR-30c
miR-21
miR-17-92
miR-191
miR-221
miR-190
miR-186
2007). These associations between phenotype and genotype are
important because tumorphenotype canbeused to identify at-risk
families.
GERMLINE DNA MUTATIONS THAT INCREASE
SUSCEPTIBILITY TO DEVELOP PANCREATIC
ADENOCARCINOMA
Most pancreatic cancers are sporadic. In sporadic forms, asso-
ciation with polymorphic somatic mutations, spontaneous, or
generated by environmental factors is of paramount importance.
It is well known that sporadic forms of cancers result from the
accumulation of genetic modiﬁcations or mutations. Besides par-
ticular syndromes whose association with pancreatic cancer is well
known, a lot of work remains to identify genetic variations asso-
ciated with cancer predisposition. Recent advances in large-scale
genotyping (SNP chips) increased considerably the number of
markers that can be simultaneously genotyped. As a consequence,
haplotype blocks can be determined much more precisely than
with microsatellite markers. These methodologies allowed recent
studies of associations covering all intragenic regions of the whole
human genome, these studies being called “genome-wide associ-
ation studies” (GWAS). Several GWAS led to the identiﬁcation of
susceptibility markers of several types of cancers (review in Mano-
lio, 2010). More than 700 GWAS are presently registered but only
four concern pancreatic cancer (Amundadottir et al., 2009; Dier-
gaarde et al., 2010; Low et al., 2010; Petersen et al., 2010). Two
GWAS for pancreatic cancer (Amundadottir et al., 2009; Petersen
et al., 2010), have been conducted within the framework of the
“pancreatic cancer cohort consortium,”or PCCC, an international
consortium comprising Centers from Europe, China, and North
America. In these studies, 12 cohorts representing more than 3800
cases of cancer and 3900 controls allowed detection of four new
genes associated with pancreatic cancer. The ﬁrst locus, harbor-
ing several SNPs strongly associated with cancer occurrence, was
localized on chromosome 9q34 and contains the ﬁrst intron of
the ABO gene. That gene encodes the glycosyl-transferase which
catalyzes the transfer of sugars to antigen H (Histo-blood group
ABO system transferase). By this mechanism, antigen H becomes
antigenA or B,depending on the nature of the sugar transferred by
theABO enzyme. In individuals from groupO, the gene ismutated
and generates a non-functional protein. Association of the ABO
gene with pancreatic cancer has already been suggested 50 years
ago in studies showing a higher frequency of pancreatic or gastric
cancer in individuals from groups A, B, or AB than from group O
(Aird et al., 1953; Marcus, 1969). That gene is also found altered
in primary tumors and metastases of pancreatic cancer (Itzkowitz
et al., 1987). More recently, the PCCC added three other regions
strongly associated with cancer (Petersen et al., 2010). The ﬁrst
one is an intergenic region of 600 kb in chromosome 13q22.1,
located between genes KLF5 and KLF12. These two members of
the Kruppel transcription factor family are involved in regulating
cell growth and transformation (Dong and Chen, 2009; Naka-
mura et al., 2009). The second region is located on 1q32.1. That
region harbors gene NR5A2 (Nuclear Receptor subfamily 5 group
Amember 2), 91 kbupstream from the gene. The receptor encoded
by gene NR5A2 is present, in adults, in the exocrine pancreas, liver,
gut, and ovaries. Its function is not completely understood. In pan-
creas,NR5A2 would contribute to the regulation of the expression
of several genes (Fayard et al., 2003). The last locus identiﬁed by
this consortium is localized at 5p15.33. SNP markers that border
this locus are within intron 13 of the CLPTM1L gene (Cleft lip and
palate transmembrane 1-like). CLPTM1L is poorly described.One
of the critical factors in the interpretation of GWAS is the ethnicity
of the studied group. PCCC studies mentioned above have been
conducted onCaucasian populations anddonot necessarily reﬂect
risk factors for other ethnic groups. In fact, a GWAS conducted by
Biobank Japan (BJJ) has evidenced a different set of markers of
pancreatic cancer (Low et al., 2010). Among loci strongly associ-
ated with the disease, three are speciﬁc to the Japanese population.
The ﬁrst one, in 6p25.3, is a 75-bp linkage disequilibrium block
containing the FOXQ1 gene [Forkhead-box (Fox)Q1]. The second
SNP showing signiﬁcant association is located within gene BICD1
(Bicaudal-D homolog 1). The last locus with a high odd-ratio cor-
responds to several SNPs that fall in the ﬁrst intron of the DPP6
gene (Dipeptidyl-peptidase 6, a member of the DPP family devoid
of the catalytic residues required for enzymatic activity but which
acts through protein–protein interactions).
Two studies have extended the results obtained by analyzing
tumor exome, including a study comparing the exomes of the pri-
mary tumor and corresponding metastases (Campbell et al., 2010;
Yachida et al., 2010). In the ﬁrst one,Yachida et al. (2010) gathered
data on the exomes of seven tumors previously characterized by
Jones et al. (2008), and compared them to data on the exomes of
the correspondingmetastases. The second studywas conducted on
13 tumors and corresponding metastases (Campbell et al., 2010).
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Information produced by these studies allowed to ﬁll in a high
resolution framework of the various modiﬁcations and rearrange-
ments that occur in theDNAof metastases, of the various underly-
ingmechanisms,on the genes potentially involved in themetastatic
process and ﬁnally on the time between the appearance of the can-
cerous cell and the occurrence of a clone with a metastatic proﬁle.
Genomic instability is apparently the main characteristic of pan-
creatic cancer (Campbell et al., 2010). DNA sequencing in tumors
and in cells at different stages of progression toward metastases
revealed that the major chromosomal rearrangement is a dupli-
cation of fragments and their insertion in opposite directions, a
phenomenon called “fold-back inversions” by the authors. The
origin of fold-back inversions is not known. A possible hypothe-
sis is that early in tumor progression telomerase activity is altered
or inhibited (Bardeesy and DePinho, 2002) generating a progres-
sive shortening of telomeres and successive cycles of breaking and
abnormal fusion of chromatids by a mechanism called “breakage–
fusion–bridge” (McClintock, 1941). These rearrangements will
determine the gain or loss of DNA and, as consequence, genomic
instability. Interestingly, these results suggest that fold-back inver-
sions arise early in tumor evolution and would trigger progression
toward metastasis (Campbell et al., 2010). These results have
shown unequivocally, for the ﬁrst time, that the pancreatic tumor
evolves from a ﬁrst (parental) clone which generates progres-
sively other sub-clones. Each sub-clone will evolve independently
by accumulating speciﬁc genetic modiﬁcations and, possibly, a
tissue-speciﬁc metastatic afﬁnity proﬁle. Establishment of a phy-
logenetic correlation between genomic alterations of tumors and
their metastases allowed drawing a kinetic of tumor progression
(Yachida et al., 2010). Unexpectedly, the mean time between aris-
ing of the founding cell and the occurrence of the ﬁrst parent clone
(non-metastasis) is 11.8 years. Another 6.8 years will be required
for one of the sub-clone to acquire the metastatic proﬁle, which
occurs about 3 years before the patient dies. These ﬁndings, if con-
ﬁrmed, have major clinical consequences. They show that, if early
detection of pancreatic cancer is possible, there is a large window
of about 10 years for therapeutic intervention.
PANCREATIC CANCER PROTECTION BY DIETARY
CHEMOPREVENTIVE AGENTS
More than two-thirds of human cancers could be prevented
by modiﬁcation of lifestyle including dietary modiﬁcation. The
dietary factors associated with increased risk of pancreatic cancer
are meat, red meat in particular, and energy. Protection is mainly
provided by fruit, vegetables, and vitamins. In recent years, more
dietary compounds have been recognized as cancer chemopre-
ventive agents because of their anti-carcinogenic activity. There-
fore, early invasion and metastasis of pancreatic cancer could be
preventable by these dietary compounds. In addition to dietary
factors, there are some chemopreventive agents such as:
CURCUMIN
Curcumin is a compound from Curcuma longa (tumeric). Cur-
cumin has recently received considerable attention due to its pro-
nounced anti-inﬂammatory, anti-oxidative, immunomodulating,
anti-atherogenic, and anti-carcinogenic activities. Curcumin sup-
presses the activation of NFκB through inhibition of IKK activity
in pancreatic cancer cells (Li et al., 2004a). Phase II trials of cur-
cumin with and without gemcitabine showed that curcumin was
well-tolerated and might have some biological activity in patients
with pancreatic cancer (Dhillon et al., 2008).
SOY ISOFLAVONES
Genistein is the main isoﬂavone found in a relatively high con-
centration in soybeans and most soy-protein products. Genis-
tein inhibits cell growth and induces apoptosis in various can-
cers including pancreatic cancer. Genistein treatment signiﬁ-
cantly inhibitedNFκBDNA-binding activity, inhibitedAkt activity
(Banerjee et al., 2005; Li et al., 2005) and signiﬁcantly down-
regulated Notch signaling, leading to the inhibition of NFκB and
induction of apoptosis in pancreatic cancer cells (Wang et al.,
2006c,e).
INDOLE-3-CARBINOL AND 3,3′-DIINDOLYLMETHANE
Indole-3-carbinol (I3C) is produced from all kinds of cabbages,
broccoli, cauliﬂower, and Brussels sprouts. I3C is biologically
active and it is easily converted in vivo to its dimeric product 3,3′-
diindolylmethane (DIM), which is also biologically active. Both
I3C and DIM inhibit cell proliferation and induce apoptotic cell
death in a variety of cancers including pancreatic cancer (Abdel-
rahim et al., 2006). I3C induces apoptosis in pancreatic cancer
cells through the inhibition of STAT3 whose activation has been
observed in human pancreatic carcinoma specimens and pancre-
atic cell line but not in normal pancreatic tissues (Lian et al.,
2004).
GREEN TEA
Consumption of green tea has been implicated in better human
health including the prevention of cancers. Green tea con-
tains several catechins including epicatechin (EC), epigallocate-
chin (EGC), epicatechin-3-gallate (ECG), and epigallocatechin-
3-gallate (EGCG). However, EGCG is among catechins the most
potent for oncogenesis inhibition and reduction of oxidative stress
(Mukhtar andAhmad,1999). By targetingmultiple signaling path-
ways including MAPK, EGFR, and NFκB, EGCG inhibits the
malignant transformation of epidermal cell lines, inhibits cell
growth, and induces apoptosis in a number of cancer cells includ-
ing pancreatic cancer cells (Mukhtar and Ahmad, 1999; Qanungo
et al., 2005; Khan et al., 2006).
RESVERATROL
Relatively high quantities of resveratrol are found in grape juice
and red wine. Resveratrol has been shown to have beneﬁcial effects
on the reduction of oxidative stress and the prevention of cancers.
Resveratrol was ﬁrst noted to be a cancer chemopreventive agent
having antioxidant and anti-tumorigenic properties (Jang et al.,
1997). Like EGCG, it is a polyphenol which can cause cell cycle
arrest in G1 in various tumor cell lines including pancreatic cancer
(Ding and Adrian, 2002).
LYCOPENE AND VITAMINS
Tomato products including ketchup, tomato juice, and pizza sauce,
are the richest sources of lycopene in the occidental diet. Dietary
intake of lycopene is associated with reduced pancreatic cancer
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risk, suggesting a role in the prevention of pancreatic cancer
(Nkondjock et al., 2005).
CURRENT TREATMENTS
Due to delayed diagnosis and aggressiveness of pancreatic cancer,
only 10% of patients are eligible for curative treatment and 90% of
patients undergo palliative therapies. Surgery, chemotherapy, and
radiotherapy are the weapons used to ﬁght pancreatic cancer, with
disappointing impact on survival though.
SURGERY
To date, surgery remains the most efﬁcient treatment. However,
only 10% of patients are eligible for resection: no distant dis-
ease (hepatic or lung metastasis) and no local vascular invasion
(mainly mesenteric vessels and celiac trunk) must be present to
consider curative resection. Palliative surgery can be performed in
selected patients but is not recommended: endoscopic derivation
(duodenal prosthesis and biliary duct stenting) has reduced the
ﬁeld of the historical twin derivation. The last two decades have
shown a dramatic reduction in postoperative morbidity and mor-
tality of pancreatic surgery. Now, pancreatic surgery performed
by experienced surgeons in high volume centers results in less
than 5% mortality. Due to reduced morbidity, pancreatic surgery
can be performed safely in elderly patients. Moreover, vascular
resection/reconstruction (only recommended for venous involve-
ment; arterial resection remains a contra indication to surgery)
is becoming safe and increases the proportion of patients elected
for pancreatic surgery. Despite appropriate surgery and perioper-
ative treatments, the 5-year overall survival after resection remains
poor and long-term survivors are rare. Yet, some progress has been
made. In the 80s, a new type of pancreatic tumorwas identiﬁed and
named IPMNs (Sohnet al., 2001). IPMNisdeﬁnedby abenign cys-
tic tumor connected with the pancreatic duct network. However,
transformation in pancreatic cancer occurs in 5–20% of IPMN
according to sub-IPMN types (side branch or main duct IPMNs).
Thus, patients diagnosed with IPMN (fortuitous diagnosis, pan-
creatitis, etc.) had to be strictly followed up or their pancreas
resected. Resection of a pre-cancerous tumor should be considered
the most efﬁcient advance in pancreatic cancer management.
CHEMOTHERAPY
Chemotherapy may be used either in the palliative setting
for metastatic or locally advanced unresectable tumors, or in
resectable disease before (neoadjuvant) or after surgery (adjuvant
treatment).
PALLIATIVE TREATMENT
Gemcitabine, a nucleoside analog, became the reference treat-
ment for advanced pancreatic cancer after a randomized trial in
which 126 chemotherapy-naïve patients with advanced disease
were randomized to receive either weekly gemcitabine or 5-FU
(Burris et al., 1997). No statistically signiﬁcant difference was
found in the overall response rate between the two groups (5.4%
for gemcitabine and 0% for 5-FU), but the number of patient who
experienced improved clinical response (improvement in pain or
performance status) was signiﬁcantly greater in the gemcitabine
group than in the 5-FU group (23.8 versus 4.8%, P = 0.0022).
Gemcitabine treatment was associated with improvement in the
median overall survival (5.65 versus 4.41months,P = 0.0025) and
1-year survival (18 versus 2%). Following this trial, several stud-
ies have evaluated in phase III randomized trials the impact of
adding a second cytotoxic compound to gemcitabine, notably 5-
FU and analogs (such as capecitabine, an oral 5-FU pro-drug;
Berlin et al., 2002; Herrmann et al., 2007; Cunningham et al.,
2009) or platinum (cisplatin or oxaliplatin) derivatives (Colucci
et al., 2002, 2010; Louvet et al., 2005; Heinemann et al., 2006;
Poplin et al., 2009). No clear survival advantage was demonstrated
in these trials, even though some of them have suggested a bene-
ﬁt in patients with good performance status (Heinemann et al.,
2008). Several classes of targeted agents have also been tested
in combination with gemcitabine and were compared to gemc-
itabine alone. In a phase III trial, the combination of erlotinib,
an orally administered EGFR tyrosine kinase inhibitor, plus gemc-
itabine versus gemcitabine alone showed statistically signiﬁcant
improvements in overall survival [6.2 versus 5.9months; haz-
ard ratio (HR): 0.82; P = 0.038] and 1-year survival (23 versus
17%, P = 0.023), leading to its approval by health authorities
for ﬁrst-line treatment of patients with advanced pancreatic can-
cer. However, the small improvement in survival, only 2weeks,
was associated with increased toxicity and therefore not consid-
ered as clinically meaningful (Moore et al., 2007), explaining why
it is barely used in the routine setting. Cetuximab, a chimeric
monoclonal antibody targeting EGFR, was also evaluated in com-
bination with gemcitabine versus gemcitabine alone, but no dif-
ference in term of response, progression-free survival, or overall
survival was observed (Philip et al., 2010). Two phase III trials
investigated the potential impact of bevacizumab, a humanized
monoclonal antibody targetingVEGF, in advanced pancreatic can-
cer patients (gemcitabine plus bevacizumab versus gemcitabine
alone; gemcitabine plus erlotinib plus bevacizumab versus gem-
citabine plus erlotinib plus placebo) but failed to demonstrate
any overall survival advantage (Van Cutsem et al., 2009; Kindler
et al., 2010). Other tested targeted agents to date, such as tip-
ifarnib (farnesyl transferase inhibitor), axitinib (multitargeted
tyrosine kinase inhibitor), matrix metalloprotease inhibitors have
generated disappointing results.
Most recently, a polychemotherapy regimen including 5-FU,
leucovorin, oxaliplatin, and irinotecan was compared to gemc-
itabine as ﬁrst-line therapy in 342 metastatic pancreatic cancer
patients, with good performance status, normal liver function and
age under 76. The median overall survival, which was the primary
endpoint, was 11.1months in the FOLFIRINOX group as com-
pared with 6.8months in the gemcitabine group [HR for death,
0.57; 95% conﬁdence interval (CI), 0.45–0.73; P < 0.001]. Median
progression-free survival was 6.4months in the FOLFIRINOX
group and 3.3months in the gemcitabine group (HR for disease
progression, 0.47; 95% CI, 0.37–0.59; P < 0.001). The objective
response rate was 31.6% in the FOLFIRINOX group versus 9.4%
in the gemcitabine group (P < 0.001). More adverse events were
noted in the FOLFIRINOX group with a higher incidence of
grade 3 or 4 neutropenia, febrile neutropenia, thrombocytope-
nia, diarrhea, and sensory neuropathy, as well as grade 2 alopecia.
At 6months, 31% of the patients in the FOLFIRINOX group
had a deﬁnitive degradation of the quality of life versus 66% in
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 2 | Article 6 | 14
Iovanna et al. Pancreatic cancer
the gemcitabine group (HR, 0.47; 95% CI, 0.30–0.70; P < 0.001;
Conroy et al., 2011). These results suggest that FOLFIRINOX
should be considered as the recommended ﬁrst-line option for
patients with metastatic pancreatic cancer and judged ﬁt to receive
it (Performance status 0–1, normal, or nearly normal bilirubin
level, age< 76).
In patients with non-metastatic locally advanced pancreatic
tumor (i.e., non-resectable), primary chemoradiation was the pre-
ferred treatment in the 90s. However, some patients received a
local treatment and were diagnosed with distant disease after
completion of chemoradiation. In addition, a French random-
ized trial comparing gemcitabine alone to chemoradiation (5-
FU+ cisplatin) followed by gemcitabine, showed a lower over-
all survival in the radiotherapy arm (Chauffert et al., 2008).
Thus, unresectable tumors are usually treated with short period
chemotherapy followed by chemoradiation in patients with non-
progressive disease. In addition, some of these patients may be
secondarily brought to surgery.
NEOADJUVANT CHEMOTHERAPY
As judged from its impact on survival, neoadjuvant treatment
is not recommended for resectable pancreatic cancer. However,
two uncontrolled phase II trials have evaluated neoadjuvant
gemcitabine-based chemotherapy alone (without radiation), with
promising results. Palmer et al. (2007) randomized 50 patients
with potentially resectable pancreatic lesions to be treated with a
short phase of weekly gemcitabine plus orminus cisplatin. Overall,
54% of patients underwent resection, 9 (38%) in the gemcitabine
arm, and 18 (70%) in the combination arm, with no increase
in surgical complications. Twelve-month survival for the gemc-
itabine and combination groups was 42 and 62% (Palmer et al.,
2007). In a prospective phase II study, Heinrich et al. (2008) tested
neoadjuvant gemcitabine–cisplatin biweekly, for four cycles in 28
patients with resectable adenocarcinoma of the pancreatic head.
Resection rate R0 was 80% and survival was increased (Heinrich
et al., 2008). However, these studies were small-sized and further
data are required before integrating preoperative chemotherapy
in the routine setting. Of course, because of the results reported
with FOLFIRINOX in advanced disease, this regimen should be
imperatively evaluated in this strategy. Neoadjuvant chemoradia-
tion was also used in phase II studies but showed poor impact on
disease progression (Gillen et al., 2010).
ADJUVANT TREATMENT
Till the mid-2000s, resection of pancreatic cancer was not rou-
tinely associated with postoperative chemotherapy. In 2004, the
ﬁnal results of a randomized trial (ESPAC-1) were reported, com-
paring surgery alone (n = 69) to chemotherapy alone (5-FU bolus
plus folinic acid, 6months; n = 75), radiochemotherapy (5-FU-
based; n = 73), or both (n = 72). The estimated 5-year survival
rate was 10% among patients assigned to receive chemoradio-
therapy and 20% among patients who did not receive chemora-
diotherapy (P = 0.05). The 5-year survival rate was 21% among
patients who received chemotherapy and 8% among patients who
did not receive chemotherapy (P = 0.009). These results indicate
that adjuvant chemotherapy provided signiﬁcant survival bene-
ﬁt in patients with resected pancreatic cancer, whereas adjuvant
chemoradiotherapy had a deleterious effect on survival (Ghaneh
and Neoptolemos, 2004). In 2007, Oettle et al. (2007) compared
weekly gemcitabine (6months) to observation after curative-
intent resection in 368 pancreatic cancer patients (CONKO-001
trial). Median disease-free survival, the primary endpoint, was
13.4months in the gemcitabine group and 6.9months in the
control group (P < 0.001, log-rank; Oettle et al., 2007). Final
results of this trial showed that this disease-free survival differ-
ence translated into an overall survival advantage (Oettle et al.,
2007). Thus, both 5-FU- and gemcitabine-adjuvant chemother-
apy improve outcome in resected pancreatic cancer. A face to
face comparative study between 5-FU and gemcitabine in this
setting revealed no difference in efﬁcacy, but 5-FU appeared
more toxic (Neoptolemos et al., 2009). Therefore, gemcitabine
is the recommended choice for adjuvant treatment, but 5-FU
may be used as an alternative in case of intolerance. Again,
after recent exciting results reported in the palliative setting,
FOLFIRINOXwill have to be evaluated as adjuvant treatment after
surgery.
RADIOTHERAPY
Radiotherapy is an efﬁcient weapon against pancreatic cancer.
However, appropriate use/timing of radiotherapywas not precisely
identiﬁed. Radiotherapy alone was not used in pancreatic cancer.
Neoadjuvant chemoradiation was performed with uneven results
in patients with resectable tumor. Several drugs were associated
to radiotherapy (5-FU, cisplatine, gemcitabine. . .) with similar
results. Patients who had had tumor resection after chemora-
diation showed histologic modiﬁcations in the removed tumor.
Moreover, sterilized specimens were sometimes observed. Thus,
chemoradiation is certainly efﬁcient in a small proportion of
patients but no factor could be identiﬁed at diagnosis to determine
which group of patient had to receive chemoradiation. To date,
chemoradiation should not be recommended in resectable tumor.
Finally, in patients with locally advanced tumor, chemoradiation
is used after inductive chemotherapy in patients with still non-
metastatic disease. However, a small proportion of patients with
locally advanced tumors are eligible for resection after completion
of chemotherapy followed by chemoradiation.
NEW STRATEGIES FOR THE TREATMENT OF PANCREATIC
CANCERS
USING GENE THERAPY TO ENHANCE CANCER CHEMOTHERAPEUTIC
EFFICACY
In recent years, gene therapy based on the knowledge of molecular
pathogenesis has been actively developed as a novel therapeutic
strategy to be used alone or in combination with conventional
chemotherapy in pancreatic cancer. Strategies for gene therapy in
pancreatic cancer include antisense and RNA interference strate-
gies whereby the function of activated oncogenes (K-ras, H-ras,
Notch, LSM1, etc.) is inhibited, and strategies to restore the func-
tion of tumor suppressor genes (p53, p16/INK4a, p21/WAF1,
DPC4/Smad4, etc.). These therapeutic strategies have shown their
promising effects on the inhibition of pancreatic cancer in vitro
and in vivo (Bhattacharyya and Lemoine, 2006). In addition,
gene-directed pro-drug activation therapy is another gene ther-
apy system in which a gene that encodes an enzyme is delivered
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to the tumor cell. Then, a pro-drug administered as chemother-
apy is metabolized by the enzyme to release cytotoxic drug at
the site of the tumor. A recent report has shown that introduc-
tion of a fusion gene combining deoxycytidine kinase and uridine
monophosphate kinase, which converts gemcitabine into its toxic
phosphorylated metabolite, sensitizes pancreatic cancer cells to
gemcitabine by reducing dramatically both in vitro cell viabil-
ity and in vivo tumor volume (Vernejoul et al., 2006). Moreover,
the combinations of gemcitabine treatment with introduction of
IFN-α, NK4, or p53 signiﬁcantly suppress the growth and the
metastasis of human pancreatic cancer cells, suggesting that the
efﬁcacy of chemotherapy in pancreatic cancer can actually be
enhanced by gene therapy (Bhattacharyya and Lemoine, 2006;
Ogura et al., 2006).
PROMISING TRIAZOLE NUCLEOSIDE COMPOUNDS TO FIGHT
DRUG-RESISTANT PANCREATIC CANCER
We initiated, several years ago, a research program to develop novel
triazole nucleoside analogs with appended aromatic systems on
the triazole base, in the view to searching for biologically active
nucleoside analogs as drug candidates against pancreatic cancer,
particularly for drug-resistant pancreatic cancer. The rationale
for molecular design was based on the following considerations.
First, nucleoside analogs show important anticancer activity; sev-
eral successful nucleoside drugs such as gemcitabine, cladribine,
capecitabine, among others, are currently used as anticancer ther-
apy (Galmarini et al., 2002). Second, triazole is an unnatural
heterocycle, and nucleosides containing triazole as nucleobase
may be more resistant to nucleos(t)ide metabolizing enzymes and
thus offer better in vivo stability. Third, triazole is considered as
a universal base capable to form base-pairs with all ﬁve natural
nucleobases, it can therefore impart triazole nucleosides much
better interaction with their biological receptors (Loakes, 2001).
Finally, appending aromatic systems to a triazole nucleobase may
yield an expanded and enlarged conjugated with advantageous
binding properties to the corresponding nucleosides for interac-
tion with biological targets through stronger and more efﬁcient
binding via larger aromatic systems. Based on all these ratio-
nales, we have designed various triazole nucleoside analogs with
appended aromatic groups on the triazole nucleobase. Their sugar
moiety is either ribose or acyclic glycogen and the triazole nucle-
obase is connected to the sugar moiety in such a way that either 3-
or 5-aryltriazole nucleoside analogs can be obtained. The aromatic
moieties are introduced on the triazole ring via direct connec-
tion (type A), triple bond bridge (type B), triazolyl ring linker
(type C), or N -arylation (type D). Appending aromatic moieties
directly on the tiazole ring provides biaryl motifs as nucleobase
in type A compounds. It is well known that biaryl motifs are
very important in medicinal chemistry. Biaryl motifs as nucle-
obase in nucleoside analogs are of great interest in the view to
exploring new nucleoside mimics. Connection of aromatic moi-
eties via triple bond bridge or triazolyl ring on the triazole ring
can offer enlarged conjugated aromatic systems as nucleobases,
and may lead to better and stronger binding with biological tar-
gets. Amine linkage between aromatic moieties and triazole ring in
type D is expected to provide some ﬂexibility to the correspond-
ing nucleobases. Altogether, these compounds provide not only
considerable structural deviation from gemcitabine on one hand,
but also important structural diversity on the other hand. They
should be a good starting point to search for novel anticancer
candidates against pancreatic cancer.
All the synthesized triazole nucleosides types A–D were ﬁrst
assessed in vitro using MTT test to evaluate their antiprolif-
erative activity on drug-sensitive (Capan2) and drug-resistant
(MiaPaCa2) human pancreatic cancer cells. Among more than
600 compounds tested, dozens of compounds showed effective
antiproliferative activity against drug-sensitive pancreatic cancer
Capan2 cells, whereas a smaller amount of compounds emerged
with effective anticancer activity against drug-resistant pancre-
atic cancer MiaPaCa2 cells. Since we are particularly interested
in identifying leads against drug-resistant pancreatic cancer, we
focused our attention on the most promising active compounds
named 1 and 2, which exhibited much better in vitro activity
than gemcitabine (Wan et al., 2009; Xia et al., 2009). Moreover,
both compounds 1 and 2 could efﬁciently inhibit tumor growth
in MiaPaCa2-xenograft nude mice after a 2-week treatment only,
with no apparent adverse effect. Further studies revealed that the
induction of caspase-dependent apoptosis represented the main
eason for the observed anticancer activity of compounds 1 and
2. Although both compounds are originally designed as nucleo-
side analogs to interfere with DNA synthesis, neither compound
1 nor compound 2 could signiﬁcantly inhibit DNA synthesis,
contrary to gemcitabine. Gemcitabine has been also reported
to down-regulate p8, a stress-associated protein with antiapop-
totic properties. However, neither compound 1 nor compound
2 could signiﬁcantly down-regulate p8 in a way similar similar
to gemcitabine. On the contrary, both of them rather upregu-
late p8 expression. These ﬁndings suggest that the mechanisms
of action of the active Triazole nucleosides compounds 1 and 2
have mechanisms of action very different from those of gem-
citabine. In fact, preliminary investigations demonstrated that
compound 2 could effectively down-regulate heat shock pro-
tein 27 (Hsp27) at both mRNA and protein levels. Hsp27 is
an ATP-independent small molecular chaperone recently recog-
nized as a novel target for anticancer therapy (Concannon et al.,
2003; Arrigo et al., 2007). It plays an important role in the
resistance shown by patients with pancreatic cancer to gemc-
itabine and its function is to protect against drug toxicity (Mori-
Iwamoto et al., 2007). Recent studies with antisense oligonu-
cleotides and siRNA molecules down-regulating Hsp27 demon-
strated potent caspase-dependent apoptotic anticancer activity
on prostate cancer (Rocchi et al., 2004, 2005). These antisense
oligonucleotides are currently in clinical trial for use in the treat-
ment of several human cancers, including lung, breast, prostate,
bladder, and ovarian cancers. An additional study with IFN-γ also
showed that down-regulation of Hsp27 via IFN-γ could gener-
ate effective anticancer activity in drug-resistant pancreatic cancer
cells, further validating the general utility and importance of
down-regulating Hsp27 in treating drug-resistant cancers (Mori-
Iwamoto et al., 2009). This represents the ﬁrst small molecular
anticancer lead with such a novel mode of action and effective
anticancer consequence, opening a new avenue in the search for
novel anticancer drug candidates to ﬁght drug-resistant pancreatic
cancer.
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CONCLUSION
The development and progression of pancreatic cancer are closely
associated with the activation of oncogenes, the inactivation of
tumor suppressor genes, the deregulation of EGFR,Akt,NFκB,and
their downstream signaling pathways. Although targeted thera-
pies for pancreatic cancer have yielded encouraging results in vitro
and in animal models, these ﬁndings have not been translated
to improved outcomes in clinical trials. Reasons for this failure
might include an incomplete understanding of the biology of
pancreatic cancer, the selection of poor active agents, problems
with trial design (such as inappropriate therapeutic end points or
patient selection) and the rapidity with which agents move into
randomized, controlled trials without the extensive early testing
necessary to optimize treatment regimens. Furthermore, preclini-
cal studies performed on mouse models do not always recapitulate
the human condition, a particularly important limitation with
human pancreatic cancer xenografts in immunodeﬁcient mice.
Despite these setbacks, lessons have been learnt, and our col-
lective effort has generated a substantial platform of knowledge
from which further work could spring. Genetically engineered
immunocompetent mice, such as those with K-RAS or TP53
mutations, have been developed and they hold promise for future
studies of the disease. The bioavailability of compounds such as
antisense oligonucleotides and siRNAs in humans remains a big
hurdle, which will require further improvement of gene-delivery
strategies.
The individualization of therapy for patients is possible if
factors that predict treatment response, such as biological mark-
ers, can be determined accurately. These approaches are likely
to comprise a mixture of targeted agents in combination with
conventional chemotherapy and radiotherapy. For a clinically sig-
niﬁcant effect to be achieved, treatment strategies should either be
in the form of a“horizontal” approach, in which several oncogenic
pathways are inhibited, or a “vertical” approach, whereby multi-
ple levels of a major pathway are targeted. Combined therapies,
together with improved diagnostic tools and predictive markers,
are ultimately hoped to improve the bleak outlook of patients
diagnosed with pancreatic cancer.
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